GLP-1 Receptor Agonists and Energy Expenditure: What Does Science Really Say?

A recent review article titled "Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review", published in Obesity Reviews (the official journal of the International Association for the Study of Obesity) by authors Vieira FT, Deng Z, Muller MJ, Bergamasco GGL, Cawsey S, Manco M, Heymsfield SB, Prado CM, and Haqq AM, sheds new light on the effects of GLP-1 receptor agonists (GLP-1RAs) on energy expenditure. But does the study deliver on its promises? We put it under the microscope – from funding sources to practical implications for your daily life.

1. Cui Bono? The Trail of Money and Interests

First, let's take a critical look behind the scenes. The funding for this review article is not explicitly mentioned in the abstract, which already raises questions. GLP-1 receptor agonists like liraglutide or semaglutide are blockbuster drugs in the pharmaceutical industry, especially in the field of diabetes and weight management. Some of the authors may have connections to pharmaceutical companies that produce such drugs – a point that would need to be examined in the full version of the study. These potential conflicts of interest could influence the selection of included studies or the interpretation of the results. It is important that you are aware: such works can unconsciously support an agenda that promotes the use of such drugs as "miracle cures." We remain vigilant and scrutinize the data thoroughly.

2. The Methodological Gauntlet: The Foundation of the Study

The study is a Scoping Review, meaning it systematically summarizes existing literature on GLP-1 receptor agonists and their impact on energy expenditure, without conducting its own meta-analysis. It is therefore not an experimental study, but an overview that attempts to map the state of research. Specific information on sample sizes or duration of the included studies is missing from the abstract, which makes evaluation difficult. However, the work focuses on mono and combination therapies, which opens up a broad perspective on various forms of drug application. Measurement methods for energy expenditure (e.g., indirect calorimetry) are not described in detail, which raises the question of data comparability. A study without uniform measurement standards is like an orchestra without a conductor – the individual instruments play, but do they harmonize? Without access to the full version, it remains unclear whether bias is present due to the selection of studies (selection bias) or due to insufficient control of confounding variables. The validity heavily depends on how stringently the authors defined their inclusion criteria.